3871 studies found for:    stage 2 breast cancer
Show Display Options
Rank Status Study
1 Recruiting FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: fluorine F 18 fluorothymidine;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis
2 Recruiting Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Patients With Stage II-IV HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Biological: sargramostim;   Drug: rintatolimod;   Other: laboratory biomarker analysis
3 Terminated Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: goserelin acetate;   Drug: letrozole;   Drug: anastrozole;   Drug: chemotherapy;   Procedure: Surgery
4 Recruiting Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Akt inhibitor MK2206;   Drug: anastrozole;   Drug: goserelin acetate;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Recruiting Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Undergoing Surgery
Condition: Breast Cancer
Interventions: Biological: HER2Bi-armed activated T cells;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
6 Completed Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
Condition: Breast Cancer
Interventions: Biological: filgrastim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Drug: tamoxifen citrate;   Procedure: adjuvant therapy;   Radiation: radiation therapy
7 Recruiting Laboratory Treated T Cells After Chemotherapy in Treating Patients With HER2-Negative Stage II-III Breast Cancer That Can Be Removed By Surgery
Conditions: Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Drug: Docetaxel;   Biological: HER2Bi-armed activated T cells;   Other: laboratory biomarker analysis;   Procedure: therapeutic conventional surgery
8 Active, not recruiting Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer
Conditions: Stage II Breast Cancer;   Stage III Breast Cancer
Intervention: Biological: Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
9 Unknown  Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer
Conditions: HER2-negative Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: bevacizumab;   Drug: paclitaxel;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Biological: pegfilgrastim
10 Recruiting Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
Conditions: Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Biological: trastuzumab;   Biological: bevacizumab;   Drug: docetaxel;   Drug: carboplatin;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
11 Terminated Pazopanib Hydrochloride and Anastrozole Before Surgery in Treating Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Drug: anastrozole;   Drug: pazopanib hydrochloride;   Procedure: therapeutic conventional surgery
12 Recruiting Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: fulvestrant;   Drug: anastrozole
13 Terminated RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: letrozole;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Procedure: therapeutic conventional surgery;   Procedure: breast biopsy;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
14 Completed Biomarkers in Women Receiving Chemotherapy and Celecoxib for Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Condition: Breast Cancer
Interventions: Biological: filgrastim;   Drug: capecitabine;   Drug: celecoxib;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Genetic: protein expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: imaging biomarker analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Procedure: needle biopsy;   Procedure: neoadjuvant therapy;   Procedure: radiomammography;   Procedure: ultrasound imaging
15 Recruiting Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm
Conditions: Breast Cancer;   Chemotherapy
Interventions: Drug: Taxotere , Epirubicin;   Drug: E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP
16 Completed Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer
Condition: Breast Cancer
Interventions: Biological: aldesleukin;   Biological: recombinant interferon gamma;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: thiotepa;   Procedure: autologous bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation
17 Completed Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: Carboplatin;   Drug: background treatment according to standards fpr triple negative and Her2pos breast cancer patients
18 Completed Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: DLBS1425;   Drug: Placebo DLBS1425
19 Completed Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Condition: Breast Cancer
Interventions: Biological: filgrastim;   Drug: CMF regimen;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: tamoxifen citrate;   Procedure: autologous bone marrow transplantation;   Procedure: surgical procedure;   Radiation: radiation therapy
20 Active, not recruiting Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: exemestane;   Drug: letrozole

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years